nmda receptor

NMDA receptor modulator9 is an orally active positive allosteric modulator (PAM) of the NMDA receptor. It enhances the activity of the GluN2A receptors. In a chronic restraint stress (CRS) induced depression mouse model, NMDA receptor modulator9 exhibits significant antidepressant-like effects. It is used for research on depression.

NMDA receptor antagonist 2 is a highly potent and orally active NR2B subtype-selective antagonist of the N-methyl-D-aspartate (NMDA) receptor, with an IC50 of 1.0 nM and a Ki value of 0.88 nM. This compound is valuable in scientific investigations of neuropathic pain and Parkinson's disease.

NMDA receptor antagonist 4 (IIc) is an uncompetitive, voltage-dependent, orally active NMDAR blocker with an IC50 of 1.93 μM. It shows positive predicted blood-brain-barrier (BBB) permeability and can be used in Alzheimer's disease research[1].

NMDA receptor modulator 2 (Compound 1) is a potent NMDA receptor modulator suitable for neurological disorder research [1].

NMDA receptor modulator 3 (Compound 99) is a potent NMDA receptor modulator useful in neurological disorder research [1].

NMDA receptor antagonist-3 is a NMDA receptor antagonist with a significan recovery rate (40.0%, at 100 μM) and safe toxicological characteristics in SH-SY5Y and human adipose mesenchymal stem cells.

NMDA receptor modulator 4 (Compound 169) is a potent NMDA receptor modulator used for neurological disorder research [1].

NMDA receptor modulator 5 (Compound 195), a potent NMDA receptor modulator, shows promise for neurological disorder research [1].

NMDA receptor antagonist 5 (Compound 10e), a potent and non-toxic agent with brain permeability, is significant for studying neurological disorders [1].

NMDA receptor regulator 6 (Compound 183) is an effective NMDA receptor regulator and has research value in neurological disorders.

NMDA receptor potentiator-1 (Compound 1368) is a subunit-selective NMDA receptor enhancer with IC50 values of 4 μM for NR2C and 5 μM for NR2D expression.

NMDA Receptor Antagonist 6 (Compound 13b) functions as an antagonist at the glycine-binding site of the NMDA receptor and demonstrates cytoneuroprotective efficacy. It safeguards PC12 cells from NMDA-induced damage and apoptosis [1].

Compound (S)-10a, a GluN2B subunit-selective NMDA receptor antagonist, exhibits a K i of 93 nM and an IC 50 of 72 nM. It is potentially useful for research into neurodegenerative diseases [1].

Compound (R)-10a, an NMDA receptor antagonist, exhibits selectivity for the GluN2B subunit, possessing a Ki of 265 nM and an IC50 of 62 nM. This compound is utilized in research pertaining to neurodegenerative diseases [1].

7-Chlorokynurenic acid (7-chloro-4-hydroxy-2-carboxyquinoline) is an effecitve and selective antagonist of NMDA receptor with IC50 of 0.56 μM for the glycine B coagonist site. 7-Chlorokynurenic acid inhibits the reuptake of glutamate into synaptic vesicles with a Ki of 0.59 μM and shows antinociceptive actions after neuraxial delivery.

CGP 78608 hydrochloride is a specific antagonist at the glycine binding site of the NMDA receptor (IC50 = 6 nM). CGP 78608 hydrochloride exhibits anticonvulsant activity. CGP 78608 hydrochloride potentiates GluN1/GluN3A-mediated glycine currents (estimated EC50 = 26.3 nM).

GV-196771A A novel NMDA receptor glycine site antagonist with potent antinociceptive activity.

SDZ 220-581 Ammonium salt is a potent, orally active, and competitive NMDA receptor antagonist (pKi: 7.7).

Nelonemdaz (Neu2000) is an NMDA receptor antagonist with antioxidant activity and neuroprotective activity used in the study of cerebral infarction reperfusion injury and acute ischemic stroke.

SDZ 220-040 is a selective mammalian NMDA receptor antagonist that induces a partially gravity-free mode of root growth.

AV-101 (4-Cl-KYN) , a prodrug antagonist at the glycine site of the NMDA receptor, has antidepressant activity and reduces levodopa-induced dyskinesia in MPTP monkeys.

LY339434 HCl is a low affinity GluR5 erythrocyte receptor agonist.LY339434 HCl causes rapid neuronal death primarily by affecting N-methyl-D-aspartate (NMDA) receptors.

BDBM50597431 is an NMDA receptor modulator that may have can be used to study Alzheimer's disease and Parkinson's syndrome.

NS-102 is a glutamate receptor and NMDA receptor antagonist that inhibits erythrocyanine (GluK2), which reduces glur6 receptor-mediated currents, and inhibits specific binding to the glur6 receptor.